New research reveals that triggering a cell’s DNA damage response could be a promising avenue for developing novel treatments against several rare but devastating viruses for which no antiviral ...

Rutgers scientists have developed a new approach to stopping viral infections: a so-called live-attenuated, replication-defective DNA virus vaccine that uses a compound known as centanamycin to ...

Researchers have shown for the first time how Merkel cell polyomavirus (MCV), which causes an aggressive skin cancer called Merkel cell carcinoma, initiates DNA replication in host cells. University ...

University of Pittsburgh researchers have shown for the first time how Merkel cell polyomavirus (MCV), which causes an aggressive skin cancer called Merkel cell carcinoma, initiates DNA replication in ...

A common hallmark of viral genome replication is a high mutation rate, which can aid in their ability to evade new treatments and acquire resistance to once-effective antiviral medications. Now, a new ...

Members of a new class of antivirals are being tested in U.S. clinical trials, and one has gained approval in Japan, but how ...

Harvard Medical School researchers have uncovered crucial insights into how an emerging class of antiviral drugs works.

Researchers use cryo-EM and optical tweezers to investigate how an antiviral interacts with the herpes simplex virus.

Rutgers scientists have developed a new approach to stopping viral infections: a so-called live-attenuated, replication-defective DNA virus vaccine that uses a compound known as centanamycin to ...